111 Capital Purchases Shares of 8,303 Guardant Health, Inc. (NASDAQ:GH)

111 Capital acquired a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 8,303 shares of the company's stock, valued at approximately $254,000.

Other hedge funds also recently modified their holdings of the company. NewEdge Advisors LLC boosted its holdings in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Guardant Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after acquiring an additional 391 shares during the period. Arizona State Retirement System boosted its holdings in shares of Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after acquiring an additional 403 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after acquiring an additional 817 shares during the period. Finally, R Squared Ltd bought a new stake in shares of Guardant Health during the fourth quarter worth approximately $26,000. Institutional investors own 92.60% of the company's stock.

Guardant Health Stock Up 4.3%

Shares of NASDAQ:GH traded up $1.97 during trading on Wednesday, hitting $47.76. 2,690,798 shares of the company were exchanged, compared to its average volume of 2,138,672. The business's 50 day moving average is $42.71 and its 200-day moving average is $40.73. The company has a market capitalization of $5.92 billion, a P/E ratio of -13.42 and a beta of 1.49. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.46) earnings per share. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Barclays lifted their price target on shares of Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, May 1st. TD Securities lifted their price target on shares of Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Scotiabank reiterated an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Morgan Stanley lifted their price target on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Twenty equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $53.29.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the sale, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 107,232 shares of company stock valued at $5,252,559 over the last 90 days. 6.10% of the stock is owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.